이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

HEC-151 주사제 단일 용량 체증 연구

2026년 9월 24일 업데이트: Sunshine Lake Pharma Co., Ltd.

단일 중심, 무작위, 위약(단일 맹검) 및 양성 대조군(개방형) 연구에서 건강한 중국인 참가자를 대상으로 HEC-151 주사제 단일 용량의 안전성, 내약성, 약동학적/약력학적 특성을 평가하는 1상 임상시험

Evaluate the safety, tolerability, PK/PD and immunogenicity characteristics of a single subcutaneous HEC-151 Injection solution in healthy participants

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

81

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Chengyong Tang, Doctor
  • 전화번호: +8618983286980
  • 이메일: 17235387@qq.com

연구 장소

    • Bishan
      • Chongqing, Bishan, 중국, 402760
        • 모병
        • No. 9, Shuangxing Avenue,, Bishan
        • 연락하다:
          • Chengyong Tang, Doctor
          • 전화번호: 8618983286980
          • 이메일: 17235387@qq.com
    • Chongqing Municipality
      • Bishan, Chongqing Municipality, 중국, 402760
        • 아직 모집하지 않음
        • No. 9, Shuangxing Avenue,
        • 연락하다:
          • Chengyong Tang, Doctor
          • 전화번호: +8618983286980
          • 이메일: 17235387@qq.com

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

남성

설명

Inclusion Criteria:

  1. Voluntarily participate in the trial and sign the informed consent form, understanding and abiding by the research procedures;
  2. When signing the informed consent form, men aged 18-45 years old (including the boundary value) are eligible;
  3. During the screening process, male subjects with a body weight of ≥ 50 kg and a body mass index (BMI) of ≥ 19.0 and ≤ 24.0 kg/m2 are included;
  4. Normal glucose tolerance [3.9 mmol/L < fasting blood glucose (FPG) < 6.1 mmol/L, and 2-hour post-glucose tolerance test (OGTT) blood glucose after sugar intake < 7.8 mmol/L];
  5. Normal results of insulin release test (IRT), or abnormal results but judged by the researcher to have no clinical significance;
  6. Glycated hemoglobin (HbA1c) < 5.7%;
  7. During the study period, there are no plans for reproduction, sperm collection, or sperm donation, and are willing to take effective contraceptive measures throughout the study period until 3 months after the administration of the investigational drug.

Exclusion Criteria:

  1. Participants with abnormal medical histories or surgical histories judged clinically significant by the researchers, or currently suffering from any diseases in the endocrine system, blood system, cardiovascular system, respiratory system, digestive system, urinary system, immune system, nervous system, etc. that are judged clinically significant by the researchers, or any other diseases or physiological conditions that can significantly affect the absorption, distribution, metabolism or excretion of the drugs;
  2. Participants who have a known severe allergic history or are allergic to the test drugs and any of their components;
  3. Participants who had severe trauma or undergone surgery within 90 days before the screening, or plan to undergo major surgery during the study;
  4. Participants who have a history of hypoglycemia or hyperglycemia within 90 days before the screening, or have a family history of diabetes (first-degree direct relatives);
  5. Participants who have donated blood or suffered significant blood loss (≥ 400 mL) within 90 days before the screening, or plan to donate blood during the study;
  6. Participants who have acute diseases or concurrent medication use from the signing of the informed consent form to the first administration of the drug;
  7. Participants whose vital signs, physical examination, laboratory tests, electrocardiogram, chest X-ray examination, etc. results are abnormal and judged by the researchers to have clinical significance;
  8. Participants whose test results for hepatitis B surface antigen (HBsAg), hepatitis C antibody (anti-HCV), combined human immunodeficiency virus antigen antibody (HIV), or syphilis spirochete antibody (TP) are positive;
  9. Participants who have a history of drug abuse or drug use, or whose urine drug screening is positive before the screening;
  10. Participants who have used any prescription drugs, Chinese herbal medicines, over-the-counter drugs, health supplements (except for regular supplementary vitamins and calcium) within 30 days before the screening;
  11. Participants who have participated in any clinical research of drugs or devices (defined as receiving the test drugs or devices) within 90 days before the screening;
  12. Participants who have received any vaccine within 30 days before the screening, or plan to receive any type of vaccine during the study;
  13. Participants who smoke more than 5 cigarettes per day within 90 days before the screening, or cannot comply with the smoking prohibition rule during the study;
  14. Participants who frequently drink alcohol, that is, consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol spirits or 150 mL of wine), or have a positive alcohol breath test; or who cannot comply with the alcohol prohibition rule during the study;
  15. Participants who consume excessive tea, coffee and/or caffeine-rich beverages (more than 8 cups, 1 cup ≈ 250 mL) or food (such as chocolate) every day within 90 days before the screening, or during the study;
  16. Participants who have used special diets (including dragon fruit, mango, pomelo, etc.) and/or xanthine diet (salmon, sardines, liver, kidney, etc.) or have other factors affecting drug absorption, distribution, metabolism, and excretion before the signing of the informed consent form to the use of the test drugs, or who cannot comply with the prohibition of eating during the study;
  17. Participants who have had significant changes in diet or exercise habits within 90 days before the screening, or have engaged in intense exercise before the signing of the informed consent form to the use of the test drugs, or cannot stop during the study;
  18. Participants who have difficulty in venous blood collection, or cannot tolerate venipuncture, or have a history of fainting or hematemesis;
  19. Participants who, in the researcher's opinion, have other factors that are not suitable for participating in this study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: HEC-151 Injection

The participants received an abdominal subcutaneous HEC-151 Injection in the morning of Day 1.

Subcutaneous injection in the abdominal area

활성 비교기: Insulin Degludec

The participants received an abdominal subcutaneous injection of Insulin Degludec in the morning of Day 1.

Subcutaneous injection in the abdominal area

위약 비교기: Placebo

The participants received an abdominal subcutaneous Injection of placebo in the morning of Day 1.

Subcutaneous injection in the abdominal area

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Adverse event
기간: From Day1 to Day36

Frequency, type and severity of adverse events/serious adverse events.

From Day1 to Day36
Electrocardiogram parameter(Heart rate)
기간: From Day1 to Day36

Evaluation the heart rate of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Electrocardiogram parameter(PR interval)
기간: From Day1 to Day36

Evaluation the PR interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Electrocardiogram parameter(QTcF interval)
기간: From Day1 to Day36

Evaluation the QTcF interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Electrocardiogram parameter(QRS interval)
기간: From Day1 to Day36

Evaluation the QRS interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Vital signs parameter(Body temperature)
기간: From Day1 to Day36

Evaluation the body temperature of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Vital signs parameter(Blood pressure)
기간: From Day1 to Day36

Evaluation the blood pressure of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Vital signs parameter(Pulse)
기간: From Day1 to Day36

Evaluation the pulse of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36
Vital signs parameter(Respiration)
기간: From Day1 to Day36

Evaluation the respiration of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group.

From Day1 to Day36

2차 결과 측정

결과 측정
측정값 설명
기간
Cmax
기간: From Day1 to Day36

Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
AUC0-t
기간: From Day1 to Day36

Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
Tmax
기간: From Day1 to Day36

Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
T1/2
기간: From Day1 to Day36

Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
CL/F
기간: From Day1 to Day36

Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
GIRmax
기간: From Day1 to Day36

Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
tGIRmax
기간: From Day1 to Day36

Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
AUCGIR
기간: From Day1 to Day36

Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants.

From Day1 to Day36
ADA(Anti-Drug Antibody)
기간: From Day1 to Day36

Evaluate the Immunogenic characteristics of HEC-151 Injection in healthy participants.

From Day1 to Day36

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 2월 24일

기본 완료 (추정된)

2026년 12월 31일

연구 완료 (추정된)

2027년 1월 31일

연구 등록 날짜

최초 제출

2026년 1월 14일

QC 기준을 충족하는 최초 제출

2026년 1월 21일

처음 게시됨 (실제)

2026년 1월 29일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 25일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 24일

마지막으로 확인됨

2026년 1월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • HEC-151-DM-101

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .